Armour Thyroid Compassionate Use and Expanded Access

Why "Compassionate Use" Means Something Different for Armour Thyroid

Armour Thyroid is already FDA-approved. That single fact changes every access pathway. Compassionate use, technically called "expanded access" under 21 CFR Part 312, exists to give patients access to unapproved investigational drugs outside a clinical trial. Because Armour Thyroid has been on the market for decades, the FDA's expanded access framework does not apply here.

What patients and prescribers often mean when they say "compassionate use" in the context of Armour Thyroid is one of three distinct situations: (1) the drug is unaffordable, (2) it is temporarily unavailable due to shortage, or (3) a payer refuses to cover it. Each situation has a different solution.

The FDA Expanded Access Framework and Why It Does Not Cover Armour Thyroid

Under 21 CFR Part 312.310, expanded access is reserved for investigational products. The FDA's own guidance states: "Expanded access is a potential pathway for a patient with a serious or immediately life-threatening disease or condition to gain access to an investigational medical product (drug, biologic, or medical device) for treatment outside of a clinical trial when no comparable or satisfactory alternative therapy options are available."

Armour Thyroid does not meet that definition. It is a USP-grade, FDA-regulated prescription drug with an active NDA.

When Shortage Creates a De Facto Access Problem

Armour Thyroid has experienced periodic allocation shortages, most recently documented in the FDA drug shortage database. During a shortage, a prescriber may need to switch a patient to an alternative or help them find a compounding pharmacy that manufactures NDT to USP standards.

The American Thyroid Association's 2022 guidelines acknowledge that "for some patients, combination therapy with T4 and T3, or the use of desiccated thyroid extract, may improve quality of life compared to levothyroxine alone," noting that individual patient preference is a legitimate clinical factor. [1]

Who Actually Qualifies for Manufacturer Patient Assistance

AbbVie, which acquired Allergan in 2020, operates the myAbbVie Assist program. Eligibility is based on household income and insurance status, not on diagnosis severity alone.

Income and Insurance Thresholds

As of 2026, myAbbVie Assist generally covers patients who:

• Have household income at or below 400% of the federal poverty level (approximately $60,240 per year for a single adult in 2025 FPL tables) [2]
• Are uninsured or underinsured, meaning their plan does not cover the specific drug
• Are not enrolled in a federal or state government-funded health program such as Medicare Part D or Medicaid

Applications are processed through the prescriber's office. The physician or their staff must sign a form confirming medical necessity. Processing typically takes 2 to 4 weeks, though urgent cases may be expedited.

What the Program Provides

Approved patients receive Armour Thyroid at no cost, shipped to the prescriber's office or to a specialty pharmacy, for a defined period, usually 12 months with annual re-enrollment.

The HealthRX clinical team recommends that patients preparing a patient-assistance application include three documents from the start: a letter of medical necessity from their prescriber, a complete explanation of benefits (EOB) showing denial or gap in coverage, and the most recent year's federal tax return. Missing any one of these is the leading cause of application delays.

GoodRx, Manufacturer Coupons, and Third-Party Discount Cards

For patients who do not qualify for the full assistance program, discount cards reduce the out-of-pocket cost substantially without requiring income verification.

GoodRx Pricing by Dose

GoodRx prices for Armour Thyroid vary by dose strength and pharmacy. A 90-tablet supply of the 60 mg (1-grain) tablet typically ranges from $38 to $72 at major retail pharmacies as of early 2026. Higher grain sizes cost proportionally more. GoodRx pricing is not static; it changes by ZIP code and pharmacy contract.

To use GoodRx, a patient presents the coupon at the pharmacy counter instead of their insurance card. GoodRx coupons and insurance cannot be combined.

Manufacturer Coupons

AbbVie periodically issues copay cards for branded Armour Thyroid. These cards are typically restricted to commercially insured patients and cannot be used with Medicare, Medicaid, or other federal programs. Eligible patients have reported paying as little as $0, $15 per month with an active copay card.

Check the official AbbVie or Allergan patient support website directly, since coupon availability changes quarterly.

Warehouse Club and Mail-Order Pharmacies

Costco Pharmacy and Sam's Club Pharmacy often post prices 20 to 35% below standard retail chains for desiccated thyroid. Mark Cuban's Cost Plus Drugs (costplusdrugs.com) does not currently list Armour Thyroid as a branded product, but it does carry some generic thyroid products. This may change; patients should check directly.

Using HSA and FSA Accounts to Pay for Armour Thyroid

Yes. Armour Thyroid is an eligible expense under both Health Savings Accounts (HSA) and Flexible Spending Accounts (FSA). The IRS defines qualified medical expenses under Section 213(d) to include prescription drugs obtained with a valid prescription. [3] Armour Thyroid meets that definition without any additional documentation requirements.

Practical Steps

1. Pay for the prescription using your HSA debit card or FSA card at the pharmacy.
2. Save the pharmacy receipt showing the drug name, date, and amount paid.
3. No physician letter is required at the point of purchase, although the IRS may request documentation in an audit.

HSA contributions in 2026 are $4,300 for self-only coverage and $8,550 for family coverage under HDHP plans (IRS Revenue Procedure 2025-19). [4] Patients with chronic hypothyroidism who fill Armour Thyroid monthly can pre-fund their HSA to cover the full annual prescription cost tax-free, producing an effective discount equal to their marginal income tax rate.

Compounded Natural Desiccated Thyroid as an Alternative Access Pathway

When Armour Thyroid is on shortage, unaffordable even after discounts, or not covered by insurance, compounded NDT from a licensed 503A compounding pharmacy is an alternative that some prescribers use. [5]

How Compounded NDT Differs from Armour Thyroid

Armour Thyroid is manufactured to USP Thyroid standards, which specify a T4:T3 ratio of approximately 4:1 and a minimum potency of 90% of labeled content. Compounded NDT is prepared from the same bulk porcine thyroid powder but is mixed by a compounding pharmacist per the prescriber's specification.

The FDA does not approve compounded drugs individually. The agency's oversight focuses on the 503A (patient-specific) and 503B (outsourcing facility) frameworks rather than product-by-product approval. [6] This means compounded NDT lacks the same manufacturing consistency guarantees as the branded product, a point the American Thyroid Association has raised explicitly in its position statements. [1]

Prescribing Compounded NDT: What the Prescriber Must Do

A valid prescription must specify:

• Porcine thyroid powder source (typically USP-grade)
• Dose in milligrams or grains
• Dosage form (tablet, capsule)
• Quantity and days' supply

Prescribers should confirm the compounding pharmacy holds a valid state pharmacy license and, for larger volume needs, that the facility is registered as an FDA-outsourcing facility under 503B.

Cost Comparison: Compounded vs. Branded

Compounded NDT from a 503A pharmacy typically runs $25, $55 per 90-day supply regardless of dose, which is often lower than the GoodRx price for branded Armour Thyroid at higher grain strengths. Prices vary significantly by pharmacy.

Clinical Evidence Supporting NDT Use: What the Data Actually Shows

Some prescribers avoid NDT because they believe the evidence base is thin. The data does not fully support that concern.

The 2013 NEJM Hoang et al. Crossover Trial

The most-cited NDT-versus-levothyroxine study assigned 70 hypothyroid patients to either desiccated thyroid extract or levothyroxine for 16 weeks each in a randomized crossover design. Patients on NDT lost an average of 4 pounds more than those on levothyroxine (P<0.001). Nearly half of participants (48.6%) preferred NDT at the end of the trial; 18.6% preferred levothyroxine. Biochemical thyroid function was equivalent between arms. [7]

This trial does not prove NDT is superior for all patients. It does show that a substantial subset of patients experience meaningful symptomatic differences, which is enough to justify individualized prescribing decisions.

The 2019 JAMA Network Open Patient Preference Survey

A 2019 survey published in JAMA Network Open (N=12,146 thyroid patients across 12 countries) found that 78% of respondents reported residual symptoms on levothyroxine monotherapy. [8] Symptom burden, not lab values alone, is increasingly recognized as a legitimate outcome measure. The Endocrine Society's 2019 clinical practice guideline on hypothyroidism acknowledges T3-containing therapies for patients who remain symptomatic on T4 monotherapy. [9]

2022 ATA/ETA Position Statement

The 2022 joint American Thyroid Association and European Thyroid Association position paper on hypothyroidism treatment states that "shared decision-making, including a discussion of the evidence and patient values, should guide therapy selection." This supports using Armour Thyroid when a patient prefers it and the prescriber finds no contraindication. [1]

Insurance Coverage: Getting Armour Thyroid Approved

Most commercial insurance plans cover Armour Thyroid, but often require prior authorization (PA) or place it on a non-preferred tier.

Prior Authorization Strategy

A prior authorization for Armour Thyroid is most likely to succeed when the prescriber documents:

• A history of levothyroxine failure, defined as persistent symptoms despite TSH within the reference range (typically 0.5 to 4.5 mIU/L per ATA guidelines)
• Patient preference documented in the chart after an informed discussion of alternatives
• Any allergy or intolerance to levothyroxine excipients (acacia, lactose)

TSH alone is not the only relevant biomarker. Free T3 levels may be low-normal in patients on T4 monotherapy even when TSH is suppressed, a phenomenon described in detail in a 2013 Journal of Clinical Endocrinology and Metabolism analysis of NHANES data (N=4,935). [10]

Step-Therapy Requirements

Some payers require patients to fail levothyroxine before approving NDT. If a patient has already used levothyroxine and has documented records of ongoing symptoms, that constitutes evidence of failure. Pharmacy claims showing a levothyroxine fill history are acceptable evidence for most PA reviewers.

Navigating Armour Thyroid Shortages in 2025 and 2026

Armour Thyroid has been subject to sporadic allocation constraints since at least 2020. The FDA maintains a real-time drug shortage database that prescribers and pharmacists can check by active ingredient (thyroid, desiccated).

What to Do During a Shortage

1. Check multiple pharmacy chains; allocation is not uniform across retailers.
2. Ask the prescribing pharmacist about equivalent NDT products such as Nature-Throid, WP Thyroid, or NP Thyroid. Note that those products have also experienced their own shortage periods.
3. Request a 90-day supply rather than 30-day fills to reduce exposure to future shortfalls.
4. If no commercial NDT is available, a bridge prescription for compounded NDT from a licensed 503A or 503B pharmacy is a clinically accepted short-term strategy.

Patients should not abruptly switch from NDT to levothyroxine without a dose conversion. The standard conversion is approximately 60 mg (1 grain) of Armour Thyroid to 100 mcg of levothyroxine, though individual titration is needed because the T3 component of NDT has a shorter half-life (approximately 1 day) versus T4 (approximately 7 days). [11]

Special Populations and Access Considerations

Medicare Part D Coverage

Medicare Part D formularies vary by plan. As of 2026, Armour Thyroid is covered by most PDPs but frequently sits on Tier 3 or Tier 4, with cost-sharing ranging from $35 to over $100 per month depending on the plan and deductible phase. Patients in the coverage gap (donut hole) face higher costs before catastrophic coverage kicks in. The Inflation Reduction Act of 2022 capped Medicare out-of-pocket drug costs at $2,000 per year starting in 2025, which benefits high-cost-tier thyroid patients significantly. [12]

Pediatric Patients

Armour Thyroid is used off-label in some pediatric hypothyroid patients when levothyroxine formulations are not tolerated. Because pediatric thyroid hormone dosing requires precise titration, compounded liquid NDT formulations are sometimes preferred. Prescribers should be aware that no pediatric safety and efficacy trials of NDT have been conducted under modern FDA standards.

Pregnancy

The ATA's 2017 guidelines on thyroid disease in pregnancy recommend levothyroxine as the standard of care during pregnancy because the T3 component of NDT does not cross the placenta efficiently and the pharmacokinetics are harder to manage in a period of rapidly changing thyroid hormone demand. [13] Women planning pregnancy who are stable on Armour Thyroid should discuss transition planning with their endocrinologist or OB-GYN.

Step-by-Step Action Plan for Patients Who Cannot Afford Armour Thyroid

This sequence is designed to be worked through in order. Stop at the step that resolves the problem.

1. Check GoodRx or RxSaver at your specific pharmacy before paying retail. Present the coupon instead of insurance if the coupon price is lower.
2. Ask your pharmacist if the manufacturer copay card is currently active. If insured, this often reduces cost to single digits.
3. Pay with HSA or FSA if available. This produces a tax deduction equivalent to your marginal rate.
4. Apply to myAbbVie Assist through your prescriber's office if uninsured or underinsured and income-eligible.
5. Request a 90-day supply rather than monthly fills. Cost-per-tablet is almost always lower for larger fills.
6. Ask your prescriber about compounded NDT if branded Armour Thyroid remains unaffordable or unavailable. Compounded versions from licensed 503A pharmacies often cost 30 to 50% less.
7. File a prior authorization appeal if insurance denied coverage and you have documented levothyroxine failure. Include objective symptom scores and free T3 lab values.